FDA official: Regulating compounding pharmacies a ‘catch-22’ for feds
This article was originally published in Scrip
One of the US FDA's top legal authorities on 11 October said her agency's hands are somewhat tied when it comes to overseeing and taking action against pharmacies breaking state laws by mass producing compounded products and shipping them across state lines, as in the case of a firm linked to making a steroid that is being blamed for sickening 170 US patients, resulting in at least 14 deaths – with those numbers growing daily.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.